Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

coachmc May. 30 at 2:01 AM

$AKTX all the longs lefts. Can you blame them? I left a few years ago. Any newcomer coming here saying it’s crazy to sell have no clue. The only ones here that are bulls are just pumpers trying to swing trade a profit. This is a phase one drug. Ask what happened to their previous pipeline? This company has burned enough good will to be where it’s at today and they will head right back down but not before they stick an offering after they milked the news for what it’s worth and RS to stay in compliance

2 · Reply

daleloyd May. 29 at 11:15 PM

$AKTX anyone that thinks this is going down to single digits is crazy. First off it was eight dollars after the reverse split before the news came out. So why would it go back down there after they got extra funding a partnership and are preparing for clinical trials?

1 · Reply

BioResearcher May. 29 at 11:03 PM

$AKTX Why do I feel like this stock will be in single digit again next week? lol I got stopped out with small loss here. Anyone here also got stopped out?

1 · Reply

IKINGAPE May. 29 at 9:31 PM

$AKTX ACCURATE ANALYSIS CONGRATS

0 · Reply

DarkPooling May. 29 at 6:30 PM

$MODD $AKTX $AGL $SVRN $FBLG chart

0 · Reply

Kirubin May. 29 at 6:11 PM

$AKTX Thank you 🐏🐏🐏

1 · Reply

daleloyd May. 29 at 6:08 PM

$AKTX adding some today for the next run up!

1 · Reply

DarkPooling May. 29 at 5:48 PM

$AKTX $USO $MLEC $KEEL single

0 · Reply

BillionaireMotion May. 29 at 5:35 PM

$AKTX $QH $DELL No stopping these

0 · Reply

Kirubin May. 29 at 4:06 PM

$AKTX All you sheep have no Idea waht’s coming up your way!🧐🫡🫢💀

0 · Reply

Akari Therapeutics trading resumes

2026-05-28T13:56:00.000Z - 2 days ago

Akari Therapeutics trading halted, volatility trading pause

May 28, 2026, 9:17 AM EDT - 2 days ago

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

2026-05-26T16:51:25.000Z - 4 days ago

Akari Therapeutics trading halted, volatility trading pause

2026-05-26T16:45:36.000Z - 4 days ago

Akari Therapeutics trading resumes

2026-05-26T14:40:48.000Z - 4 days ago

3 Penny Stocks to Watch Now, 5/26/26

LFS QTEX

2026-05-22T19:38:16.000Z - 8 days ago

Akari Therapeutics Stock (AKTX) Explodes 242% on Strong Cancer Drug Data and $5.5M Funding Boost

2026-05-22T17:50:10.000Z - 8 days ago

Akari Therapeutics trading resumes

2026-05-22T17:45:57.000Z - 8 days ago

Akari Therapeutics trading halted, volatility trading pause

May 22, 2026, 8:00 AM EDT - 8 days ago

Akari Therapeutics, Proxy statement: Proxy filing

May 21, 2026, 5:01 PM EDT - 8 days ago

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

May 21, 2026, 8:30 AM EDT - 9 days ago

Akari Therapeutics Announces $5.5 Million Private Placement Offering

May 19, 2026, 7:00 AM EDT - 11 days ago

Akari Therapeutics, Quarterly report: Q1 2026

May 18, 2026, 9:05 AM EDT - 12 days ago

Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase

2026-05-12T13:57:28.000Z - 18 days ago

Akari Therapeutics secures European patent for Thailanstatin-based payloads

May 12, 2026, 8:33 AM EDT - 18 days ago

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

May 8, 2026, 8:00 AM EDT - 22 days ago

Akari Therapeutics, Registration statement: Registration filing

2026-04-27T13:27:26.000Z - 4 weeks ago

Akari Therapeutics receives Australian patent for core payload technology

Apr 27, 2026, 8:35 AM EDT - 4 weeks ago

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Apr 21, 2026, 9:00 AM EDT - 5 weeks ago

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

2026-04-20T14:32:23.000Z - 5 weeks ago

Akari Therapeutics announces presentation of preclinical data for AKTX-101

Apr 20, 2026, 8:35 AM EDT - 5 weeks ago

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

2026-04-09T13:05:47.000Z - 7 weeks ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

Apr 9, 2026, 8:50 AM EDT - 7 weeks ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

2026-04-08T12:08:04.000Z - 7 weeks ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

2026-04-06T13:20:35.000Z - 7 weeks ago

Akari Therapeutics announces strategic partnership with WuXi XDC

Apr 6, 2026, 8:45 AM EDT - 7 weeks ago

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

2026-04-01T10:13:11.000Z - 2 months ago

Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

2026-03-30T23:51:11.000Z - 2 months ago

Akari Therapeutics trading halted, news pending

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Akari Therapeutics, Annual report: Q4 2025

Mar 18, 2026, 8:05 AM EDT - 2 months ago

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

Akari Therapeutics Announces ADS Ratio Change

Mar 13, 2026, 9:15 AM EDT - 2 months ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

2026-02-26T14:24:15.000Z - 3 months ago

Akari Therapeutics appoints Gokhale to its Scientific Advisory Board

Feb 26, 2026, 9:10 AM EST - 3 months ago

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

2026-02-23T13:53:01.000Z - 3 months ago

Akari Therapeutics appoints Olga Anczukow to SAB

Feb 18, 2026, 9:05 AM EST - 3 months ago

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Feb 12, 2026, 7:00 AM EST - 3 months ago

Akari Therapeutics, Slides: Corporate presentation

Feb 11, 2026, 8:45 AM EST - 3 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Feb 10, 2026, 7:00 PM EST - 3 months ago

Akari Therapeutics, Transcript: Study update

Feb 10, 2026, 7:00 PM EST - 3 months ago

Akari Therapeutics, Press release: Study update

Feb 5, 2026, 9:15 AM EST - 4 months ago

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 2, 2026, 7:00 AM EST - 4 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Jan 26, 2026, 8:45 AM EST - 4 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 23, 2026, 7:00 AM EST - 4 months ago

Akari Therapeutics, Registration statement: Registration Filing

Jan 22, 2026, 7:00 AM EST - 4 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Jan 9, 2026, 9:00 AM EST - 5 months ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 8, 2026, 9:15 AM EST - 5 months ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

Dec 30, 2025, 9:15 AM EST - 5 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Dec 23, 2025, 8:30 AM EST - 5 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 18, 2025, 8:30 AM EST - 5 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Dec 16, 2025, 9:29 AM EST - 5 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Dec 9, 2025, 8:40 AM EST - 6 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Dec 4, 2025, 9:00 AM EST - 6 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 6 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Nov 18, 2025, 8:35 AM EST - 6 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Nov 17, 2025, 7:00 AM EST - 6 months ago

Akari Therapeutics, Registration statement: Registration Filing

Nov 17, 2025, 7:00 AM EST - 6 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 13, 2025, 12:00 AM EST - 7 months ago

Akari Therapeutics, Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 7 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 7, 2025, 7:00 AM EST - 7 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 4, 2025, 9:25 AM EST - 7 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Oct 30, 2025, 8:35 AM EDT - 7 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 22, 2025, 9:05 AM EDT - 7 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 8 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 8 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 8 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 8 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 5, 2025, 6:45 AM EDT - 9 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Akari Therapeutics, Registration statement: Registration Filing

Aug 14, 2025, 9:15 AM EDT - 10 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Akari Therapeutics, Quarterly report: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 10 months ago

Akari Therapeutics, Registration statement: Registration Filing

Jul 23, 2025, 8:55 AM EDT - 11 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 11 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 1 year ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 13, 2025, 5:14 PM EDT - 1 year ago

Akari Therapeutics, Slides: Company Presentation

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

May 29, 2025, 2:20 PM EDT - 1 year ago

Akari Therapeutics, Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

May 29, 2025, 9:15 AM EDT - 1 year ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 23, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

May 22, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics, Earnings release: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics, Quarterly report: Q1 2025

May 15, 2025, 8:05 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Registration statement: Registration Filing

May 1, 2025, 8:45 AM EDT - 1 year ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 1 year ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

coachmc May. 30 at 2:01 AM

2 · Reply

daleloyd May. 29 at 11:15 PM

1 · Reply

BioResearcher May. 29 at 11:03 PM

$AKTX Why do I feel like this stock will be in single digit again next week? lol I got stopped out with small loss here. Anyone here also got stopped out?

1 · Reply

IKINGAPE May. 29 at 9:31 PM

$AKTX ACCURATE ANALYSIS CONGRATS

0 · Reply

DarkPooling May. 29 at 6:30 PM

$MODD $AKTX $AGL $SVRN $FBLG chart

0 · Reply

Kirubin May. 29 at 6:11 PM

$AKTX Thank you 🐏🐏🐏

1 · Reply

daleloyd May. 29 at 6:08 PM

$AKTX adding some today for the next run up!

1 · Reply

DarkPooling May. 29 at 5:48 PM

$AKTX $USO $MLEC $KEEL single

0 · Reply

BillionaireMotion May. 29 at 5:35 PM

$AKTX $QH $DELL No stopping these

0 · Reply

Kirubin May. 29 at 4:06 PM

$AKTX All you sheep have no Idea waht’s coming up your way!🧐🫡🫢💀

0 · Reply

Kirubin May. 29 at 1:54 PM

$AKTX offering at $6 coming up!🥶

1 · Reply

topstockalerts May. 29 at 12:35 PM

$AKTX $30’s next?

1 · Reply

BioResearcher May. 29 at 12:30 PM

$AKTX AKRX's drug is next-generation ADC. It has shown far better than the traditional ADCs in both safety and efficacy.

0 · Reply

ProfessorDman1 May. 29 at 12:22 PM

$AKTX $MASK $OLOX $PRFX $SPRC ( CDT next runner bottomed buy ins now.. under accumulations

0 · Reply

BioResearcher May. 29 at 12:17 PM

$AKTX AKTX 's drug can treat many types of cancers: AKTX drug can target multiple types of solid tumors because they are Antibody-Drug Conjugates (ADCs) that home in on widespread surface proteins (like TROP2 or CEACAM5) and deliver a novel payload (PH1) that disrupts RNA splicing—a fundamental process all cancer cells depend on

0 · Reply

BioResearcher May. 29 at 11:53 AM

$AKTX Trodelvy was acquired by Gilead Sciences in October 2020 for $21 BILLIONS. AKTX's drug has shown to be better than Trodelvy in both safety and efficacy:

1 · Reply

Trader1141 May. 29 at 9:51 AM

$PRFX $AKTX $NEXR $MASK Technology stocks on 🔥 Don’t forget about $NXL

0 · Reply

Bulltrader23 May. 29 at 9:41 AM

$AKTX looking good here massive upside Potential pre market play at the least today GL 🎉💰

0 · Reply

bullish87665 May. 29 at 8:41 AM

$AKTX Are they diluting?

1 · Reply

MustLoveStocks May. 29 at 4:15 AM

$AKTX if the spreads tighten up this could rip on that cancer news. Definitely watching it and the level 2 closely tomorrow

0 · Reply

ProfessorDman1 May. 29 at 3:16 AM

CDT = I would highly recommend to keep this bottomed chart oversold low floater on your radar tomorrow: sub 1M float … on the menu for 100%-1000% range … $AKTX $PRFX $MASK $OLOX $SPRC

0 · Reply

semiguy May. 29 at 2:32 AM

$COST $ONDS $AKTX $PYPL I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026

0 · Reply

Market Cap	25.24M
Revenue (ttm)	0.00
Net Income (ttm)	-17.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	546,600
Avg Vol	950,094
Day's Range	N/A - N/A
Shares Out	1.15M
Stochastic %K	51%
Beta	0.64
Analysts	Sell
Price Target	$27.00